Search
Now showing items 1-8 of 8
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.
(2017-11)
BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
Validation of an environmentally-friendly and affordable cardboard 9-hole peg test.
(2017-10)
BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
(2016-10)
There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...
Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
(2020-10-09)
Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Methods: Case report. Results: A 53-year-old ...
Organic solvents and Multiple Sclerosis: the doubled risk dilemma.
(2023-09-29)
BACKGROUND: Compensation for industrial disease in the UK may be obtained in two ways. A State scheme includes a list of accepted associations between occupations and diseases with evidence of a causative association. ...